Genipin and UV-CLX is safe and effective for keratoconus

Article

Genipin and UV-riboflavin crosslinking (UV-CLX) is a safe and effective procedure for keratoconus

Genipin and UV-riboflavin crosslinking (UV-CLX) is a safe and effective procedure for keratoconus, claims a study in Molecular Vision.

Dr Marcel Y. Avila et al., Department of Ophthalmology, Facultad de Medicina, Universidad Nacional de Colombia, Bogota, Colombia, separated porcine eyes into three groups comprising genipin 0.25% UV-CLX (clinical crosslinking procedure), a glutaraldehyde 0.1% (gold standard crosslinker) and control.

A pressure sensor cannulated to the anterior chamber continuously monitored all groups. Changes in ocular pressure due to ocular volume were evaluated. The exponential of polynomial quadratic fit was used to calculate ocular rigidity. A viability assay with alizarin red staining was used to assess endothelial damage.

In the genpin and UV-CLX globes where the cornea was stiffened there were significant changes in IOP. Mean ocular rigidity coefficient was 0.0078 mmHg/μL for genpin, 0.0065 mmHg/μL for UV-CLX, 0.0092 mmHg/μL for glutaraldehide and 0.0046 mmHg/μL for control eyes.

In the control group endothelial damage was 5.9±1.8%, 10.3±1.7% in UV-CLX, 9.4±1.5% in Genipin 0.25% and 40.1±6.2% in glutaraldehide. In the UV-CLX group there was a significant reduction of keratocites.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.